Aastrom Biosciences Inc.
Description Aastrom Biosciences, Inc., a development stage company, engages in the development of patient-specific, cell products for use in the treatment of severe, chronic ischemic cardiovascular diseases. It is developing ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. The companys ixmyelocel-T is in late-stage clinical development, including a Phase III clinical program to study patients with critical limb ischemia and a Phase IIb clinical trial in patients with ischemic dilated cardiomyopathy. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan. To view the detailed information, you need to SUBSCRIBE with us. |
 |